The role of Capon in multiple myeloma
Yaodong Shen1, Haiyan Liu1, Siyu Gu1
11 Department of Hematology, Affiliated Hospital of Nantong University, Nantong University, Nantong, P.R. China.
Abstract:
Capon is a ligand protein of nitric oxide synthase 1. Recently, studies have shown that Capon is involved in the development of tumors. It is independent of the regulation of nitric oxide synthase 1 in this process. At the same time, studies have found that nitric oxide synthase 1 is expressed in multiple myeloma, but its role in the development and progression of myeloma remains unclear. In this study, we found that there was a different expression of Capon between the normal multiple myeloma cells and the adherent multiple myeloma cells. In the process of myeloma cell proliferation, the reduced expression of Capon reduces the arrest of the cell cycle in the G1 phase and promotes the proliferation of myeloma cells. Cell adhesion-mediated drug resistance is one of the most important factors, which affect the chemotherapy effect of multiple myeloma. If the expression of Capon is decreased, myeloma cells are adhered to fibronectin or bone marrow stromal cells (bone marrow mesenchymal stem cells). In addition, the sensitivity of the cell line to chemotherapeutic agents was reduced after silencing Capon in the myeloma cell line which was adhered to bone marrow mesenchymal stem cells. We also found that reduced expression of Capon resulted in the activation of the AKT signaling pathway. In conclusion, these results may be helpful in studying the role of Capon in multiple myeloma.
Insights
Capon protein is newly found to promote multiple myeloma cell proliferation and drug resistance by affecting cell cycle and AKT signaling. Reduced Capon expression aids myeloma cell adhesion and chemotherapy resistance.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Capon protein, a nitric oxide synthase 1 (NOS1) ligand, is implicated in tumor development, independent of NOS1.
- Nitric oxide synthase 1 (NOS1) is expressed in multiple myeloma, but its specific role in disease progression is unknown.
Purpose of the Study:
- To investigate the role of Capon in multiple myeloma (MM) cell proliferation, adhesion, and drug resistance.
- To explore the relationship between Capon expression and the AKT signaling pathway in MM.
Main Methods:
- Comparative analysis of Capon expression in normal vs. adherent multiple myeloma cells.
- Assessment of cell cycle progression and proliferation following Capon silencing.
- Evaluation of myeloma cell adhesion to fibronectin and bone marrow stromal cells.
- Chemosensitivity assays after Capon knockdown in adherent MM cells.
- Analysis of AKT signaling pathway activation.
Main Results:
- Differential expression of Capon observed between normal and adherent multiple myeloma cells.
- Reduced Capon expression promotes myeloma cell proliferation by decreasing G1 phase cell cycle arrest.
- Decreased Capon expression enhances myeloma cell adhesion to fibronectin and bone marrow stromal cells.
- Silencing Capon reduces chemosensitivity in myeloma cells adhered to bone marrow stromal cells.
- Reduced Capon expression leads to activation of the AKT signaling pathway.
Conclusions:
- Capon plays a significant role in multiple myeloma progression, influencing cell proliferation and drug resistance.
- Capon downregulation contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma.
- The AKT signaling pathway is involved in the effects of Capon on myeloma cells.
More Related Videos
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...